David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Nike
NKE
$58.6B
| $9.13M | 0.01% |
108,384
+22,444
| +26% | +$1.85M |
|
1127
Magnite
MGNI
$3.43B
| $9.12M | 0.01% |
1,500,514
+259,125
| +21% | +$1.33M |
|
1128
Calix
CALX
$2.51B
| $9.12M | 0.01% |
1,184,371
-81,116
| -6% | -$715K |
|
1129
Regis Corp
RGS
$66.8M
| $9.1M | 0.01% |
23,125
-4,863
| -17% | -$1.8M |
|
1130
CALL
Kohl's
KSS
$2B
| $9.08M | 0.01% |
132,000
-23,900
| -15% | -$1.62M |
|
1131
Axalta
AXTA
$7.79B
| $9.06M | 0.01% |
359,274
+304,692
| +558% | +$7.84M |
|
1132
PUT
Alcoa
AA
$13.5B
| $9.05M | 0.01% |
321,300
-21,000
| -6% | -$601K |
|
1133
CALL
Trade Desk
TTD
$6.23B
| $9.05M | 0.01% |
457,000
+400,000
| +702% | +$6.55M |
|
1134
CALL
Domino's
DPZ
$11.6B
| $9.03M | 0.01% |
35,000
-52,400
| -60% | -$13.6M |
|
1135
CALL
Ubiquiti
UI
$34.9B
| $8.98M | 0.01% |
60,000
+30,000
| +100% | +$3.79M |
|
1136
Highwoods Properties
HIW
$3.52B
| $8.93M | 0.01% |
190,953
-116,877
| -38% | -$5.21M |
|
1137
Novartis
NVS
$304B
| $8.92M | 0.01% |
103,545
-703,162
| -87% | -$56.4M |
|
1138
PUT
EOG Resources
EOG
$77B
| $8.92M | 0.01% |
93,700
+67,500
| +258% | +$6.43M |
|
|
JCP
1139
DELISTED
J.C. Penney Company, Inc.
JCP
| $8.9M | 0.01% |
5,974,158
+5,944,971
| +20,369% | +$8.37M |
|
1140
Fortis
FTS
$28.1B
| $8.89M | 0.01% |
240,387
-131,120
| -35% | -$4.66M |
|
1141
Constellium
CSTM
$3.67B
| $8.87M | 0.01% |
1,111,342
+245,325
| +28% | +$2.1M |
|
1142
Archer Daniels Midland
ADM
$38.2B
| $8.87M | 0.01% |
+205,617
| New | +$8.79M |
|
1143
Unisys
UIS
$196M
| $8.86M | 0.01% |
759,434
-347,209
| -31% | -$4.48M |
|
|
MODN
1144
DELISTED
MODEL N, INC.
MODN
| $8.86M | 0.01% |
505,180
-36,270
| -7% | -$580K |
|
1145
Ingredion
INGR
$6.62B
| $8.83M | 0.01% |
93,266
+87,931
| +1,648% | +$8.31M |
|
1146
Interface
TILE
$2.25B
| $8.8M | 0.01% |
574,650
+9,137
| +2% | +$150K |
|
1147
PUT
Deere & Co
DE
$170B
| $8.76M | 0.01% |
54,800
-270,500
| -83% | -$43.2M |
|
1148
Bio-Techne
TECH
$11.3B
| $8.73M | 0.01% |
175,952
-134,236
| -43% | -$6.04M |
|
1149
HEICO Corp
HEI
$49.1B
| $8.73M | 0.01% |
92,047
+42,638
| +86% | +$3.72M |
|
1150
CALL
Boston Beer
SAM
$1.95B
| $8.72M | 0.01% |
29,600
+19,600
| +196% | +$5.36M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.